Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Non Operating Income (2020 - 2022)

Terns Pharmaceuticals filings provide 3 years of Non Operating Income readings, the most recent being -$786000.0 for Q4 2022.

  • Quarterly Non Operating Income fell 1309.23% to -$786000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$282000.0 through Dec 2022, down 366.04% year-over-year, with the annual reading at -$93000.0 for FY2025, 100.7% down from the prior year.
  • Non Operating Income hit -$786000.0 in Q4 2022 for Terns Pharmaceuticals, down from $485000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $2.4 million in Q4 2020 and bottomed at -$786000.0 in Q4 2022.
  • Average Non Operating Income over 3 years is $190666.7, with a median of $52000.0 recorded in 2021.
  • Peak annual rise in Non Operating Income hit 12025.0% in 2022, while the deepest fall reached 1309.23% in 2022.
  • Terns Pharmaceuticals' Non Operating Income stood at $2.4 million in 2020, then tumbled by 97.27% to $65000.0 in 2021, then crashed by 1309.23% to -$786000.0 in 2022.
  • Per Business Quant, the three most recent readings for TERN's Non Operating Income are -$786000.0 (Q4 2022), $485000.0 (Q3 2022), and -$54000.0 (Q2 2022).